CellAct Pharma GmbH
http://www.cellact.eu/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CellAct Pharma GmbH
Deals Shaping The Medical Industry, September 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.
Mundipharma Acquires 'Smart' Chemo Drug From CellAct
Mundipharma has acquired a next-generation chemotherapy agent from German biotech CellAct to further expand its oncology portfolio.
CellAct Pharma GMBH
CellAct Pharma GMBH is developing drug candidates for cancer and immune-modulated inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and transplant rejection. Its lead compound targets topoisomerases and is in clinical Phase I study for the treatment of cancer. The company is also developing antibodies against surface molecules in lymphocytes to treat inflammation.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals